McKesson reported preliminary results for the quarter ended September 30, 2026, with consolidated revenues of $111.0 billion, an 8% increase year-over-year. Earnings per diluted share rose to $10.44 from $8.92, while adjusted earnings per diluted share increased 18% to $11.68. The company generated $3.1 billion in operating cash flow and raised its full-year adjusted EPS guidance range to $45.60-$46.40 from the previous $44.20-$45.00. Additionally, McKesson completed the acquisition of Precision Medicine Group and signed a definitive agreement for a minority investment in Option Care Health. McKesson Corporation is a diversified healthcare services leader providing pharmaceutical distribution, medical supplies, and technology solutions.
